Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Avatrombopag Maleate

FDA-approved product (tablet, oral), marketed as Doptelet, Doptelet Sprinkle.

Registered studies
6
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Avatrombopag Maleate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Hemorrhage
  • Liver disease
  • Thrombocytopenia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other systemic hemostatics
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA, K. pneumoniae and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli52.5% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae40.8% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis65.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

6registered studies name this medicine, for any condition. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Avatrombopag Maleate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Avatrombopag Maleate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Avatrombopag vs. Placebo for CIT in GI Malignancies

    NCT05772546 · start 2023-11-01

    Registered record
    Registry ID
    NCT05772546
    Conditions
    Gastrointestinal Cancer; Gastrointestinal Neoplasms; Chemotherapy-Induced Thrombocytopenia
    Interventions
    Avatrombopag; Matching Placebo
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2023-11-01
    Completion
    2026-04-20
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionGastrointestinal Cancer; Gastrointestinal Neoplasms; Chemotherapy-Induced Thrombocytopenia
    InterventionAvatrombopag; Matching Placebo
    PhasePhase 2
    Registry statusCompleted

  • Efficacy of Avatrombopag in Thrombocytopenic Patients With Chronic Liver Disease Undergoing an Elective Procedure

    NCT04915287 · start 2021-06-06

    Registered record
    Registry ID
    NCT04915287
    Conditions
    Thrombocytopenia; Drugs; Chronic Liver Disease
    Interventions
    Avatrombopag maleate; Platelet transfusion; Medicine
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Unknown
    Start
    2021-06-06
    Completion
    2023-07-31
    Enrolment
    476

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombocytopenia; Drugs; Chronic Liver Disease
    InterventionAvatrombopag maleate; Platelet transfusion; Medicine
    PhasePhase 4
    Registry statusUnknown

  • A Open-label, Three-period, Partial-replicate Design Study to Evaluate the Inter- and Intrasubject Variability of the Avatrombopag To-be-marketed Formulation Administered as Single Doses of 40 mg to Healthy Subjects Receiving a Low-fat Meal

    NCT01759394 · start 2012-10

    Registered record
    Registry ID
    NCT01759394
    Conditions
    Healthy Volunteers
    Interventions
    Avatrombopag maleate 40 mg
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2012-10
    Completion
    2013-03
    Enrolment
    36

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionHealthy Volunteers
    InterventionAvatrombopag maleate 40 mg
    PhasePhase 1
    Registry statusCompleted

  • A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

    NCT01433978 · start 2012-03-26

    Registered record
    Registry ID
    NCT01433978
    Conditions
    Idiopathic Thrombocytopenic Purpura
    Interventions
    Eltrombopag; Avatrombopag; Standard of care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Terminated
    Start
    2012-03-26
    Completion
    2013-09
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionIdiopathic Thrombocytopenic Purpura
    InterventionEltrombopag; Avatrombopag; Standard of care
    PhasePhase 3
    Registry statusTerminated

  • Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)

    NCT01438840 · start 2012-02-16

    Registered record
    Registry ID
    NCT01438840
    Conditions
    Chronic Thrombocytopenia; Immune Thrombocytopenia
    Interventions
    Avatrombopag; Placebo; Standard of care
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2012-02-16
    Completion
    2014-03
    Enrolment
    49

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChronic Thrombocytopenia; Immune Thrombocytopenia
    InterventionAvatrombopag; Placebo; Standard of care
    PhasePhase 3
    Registry statusCompleted

  • Chronic Hepatitis C Virus Related Thrombocytopenia to Evaluate the Effects of E5501

    NCT01355289 · start 2011-11

    Registered record
    Registry ID
    NCT01355289
    Conditions
    Thrombocytopenia
    Interventions
    Avatrombopag; Placebo; Pegylated interferon (PEG-IFN); Telaprevir; Ribavirin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2011-11
    Completion
    2014-05
    Enrolment
    65

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionThrombocytopenia
    InterventionAvatrombopag; Placebo; Pegylated interferon (PEG-IFN); Telaprevir +1 more
    PhasePhase 2
    Registry statusCompleted